These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17233530)

  • 41. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study.
    Takano A; Gulyás B; Varnäs K; Little PB; Noerregaard PK; Jensen NO; Elling CE; Halldin C
    Synapse; 2014 Mar; 68(3):89-97. PubMed ID: 24293119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.
    Schoffelmeer AN; Hogenboom F; Wardeh G; De Vries TJ
    Neuropharmacology; 2006 Sep; 51(4):773-81. PubMed ID: 16806307
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.
    Golech SA; McCarron RM; Chen Y; Bembry J; Lenz F; Mechoulam R; Shohami E; Spatz M
    Brain Res Mol Brain Res; 2004 Dec; 132(1):87-92. PubMed ID: 15548432
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists.
    Kang SY; Lee SH; Seo HJ; Jung ME; Ahn K; Kim J; Lee J
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2385-9. PubMed ID: 18337096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.
    Cippitelli A; Bilbao A; Hansson AC; del Arco I; Sommer W; Heilig M; Massi M; Bermúdez-Silva FJ; Navarro M; Ciccocioppo R; de Fonseca FR;
    Eur J Neurosci; 2005 Apr; 21(8):2243-51. PubMed ID: 15869521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.
    Carpino PA; Griffith DA; Sakya S; Dow RL; Black SC; Hadcock JR; Iredale PA; Scott DO; Fichtner MW; Rose CR; Day R; Dibrino J; Butler M; Debartolo DB; Dutcher D; Gautreau D; Lizano JS; O'connor RE; Sands MA; Kelly-Sullivan D; Ward KM
    Bioorg Med Chem Lett; 2006 Feb; 16(3):731-6. PubMed ID: 16263283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
    Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands.
    Murineddu G; Asproni B; Corona P; Piras S; Lazzari P; Ruiu S; Legnani L; Toma L; Pinna GA
    Molecules; 2019 Apr; 24(9):. PubMed ID: 31035548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors.
    Mollica A; Pelliccia S; Famiglini V; Stefanucci A; Macedonio G; Chiavaroli A; Orlando G; Brunetti L; Ferrante C; Pieretti S; Novellino E; Benyhe S; Zador F; Erdei A; Szucs E; Samavati R; Dvrorasko S; Tomboly C; Ragno R; Patsilinakos A; Silvestri R
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):444-451. PubMed ID: 28097916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
    Janero DR; Korde A; Makriyannis A
    Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.
    Wiley JL; Jefferson RG; Grier MC; Mahadevan A; Razdan RK; Martin BR
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1013-22. PubMed ID: 11181936
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CB1 cannabinoid receptor-mediated modulation of food intake in mice.
    Wiley JL; Burston JJ; Leggett DC; Alekseeva OO; Razdan RK; Mahadevan A; Martin BR
    Br J Pharmacol; 2005 Jun; 145(3):293-300. PubMed ID: 15778743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Binding properties of antagonists to cannabinoid receptors in intact cells.
    Wennerberg M; Cheng L; Hjorth S; Clapham JC; Balendran A; Vauquelin G
    Fundam Clin Pharmacol; 2011 Apr; 25(2):200-10. PubMed ID: 20608998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands.
    Zhang Q; Ma P; Wang W; Cole RB; Wang G
    Drug Metab Dispos; 2005 Apr; 33(4):508-17. PubMed ID: 15616153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blocking the cannabinoid receptors: drug candidates and therapeutic promises.
    Muccioli GG
    Chem Biodivers; 2007 Aug; 4(8):1805-27. PubMed ID: 17712820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
    Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
    Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A method for parallel solid-phase synthesis of iodinated analogs of the cannabinoid receptor type I (CB₁) inverse agonist rimonabant.
    Spivey AC; Tseng CC
    Methods Enzymol; 2010; 485():499-525. PubMed ID: 21050934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T; Thomas BF; Zhang Y
    Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabinoid receptor antagonists and obesity.
    Black SC
    Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.